Compare Amer Sports Inc (AS) vs GSK plc (GSK) Price & Performance

Amer Sports (AS) trades at $33.47, down 7.46% over 24 hours amid a bearish technical signal. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $0.38 surpassing expectations. Revenue growth remains strong at 32% year-over-year in Q1 2026, and the company raised its full-year guidance. Analyst consensus is overwhelmingly bullish with a $58.67 price target, though technical indicators suggest near-term weakness.

The outlook is positive given robust fundamentals and upward earnings revisions, but risks include execution on growth targets and market volatility. The current price presents a potential entry point relative to analyst targets, though investors should monitor the upcoming Q2 2026 earnings report on August 18, 2026, for confirmation of continued momentum.

GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.

The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.